Press release
US CNS Disorders Drug Pipeline Insight 2014
Within the CNS market, the biggest therapeutic area is the market for anti-psychotics, followed by anti-depressive and mood stab markets. Anti-epileptic and anti-Alzheimer’s markets come next while other classes of drugs have a marginal share. Antipsychotics have a market share of nearly 30% while antidepressants corner about 25% of the market. Anti convulsants have about 17% of the market share while drugs used in Alzheimer's Disease form about 9% of the market, with ADHD and narcolepsy drugs medications have about 7% market share. The other classes of drugs have market shares of less than 5% each.
Download Report:
http://www.pnspharma.com/buy-report.php?reporttitle=US-CNS-Disorders-Drug-Pipeline-Insight-2014
New technology including advancements in stem cell therapy and of nanotechnology is expected to drive the growth of the CNS market. Nanotechnology in the form of the nanomaterials for wound care, drug delivery and immunomodulation is specifically seen as a positive influence on CNS therapy that is expected to open growth opportunities. While each of these therapeutic subcategories are served by established treatments there are certain markets segments with significant unmet medical needs still remain, indicating potential in these areas. There are newer treatment methodologies under development such as that using stem cell therapy and of nanotechnology that seek to address these opportunities.
The rapid advances in the R&D segment, many novel drugs are currently available for the treatment of CNS disorders. Industry related to CNS drug delivery system has also got a boost due to rapid advancement of CNS disorders market. Given the magnitude of number of patients and demand for better drugs is going to push pharmaceutical companies for significant investments. Changing life-style is one the main contributor of CNS disorders in US. Increased longevity and ageing population along with launch of novel drugs will drive the growth of CNS disease market in future.
“US CNS Disorders Drug Pipeline Insight 2014” Report Highlight:
* Market Overview & Incidence by Disease
* CNS Disorder Market Dynamics
* CNS Disorder Pipeline by disease, Phase & Company
* CNS Disorder Pipeline: 1083 Drugs in Pipeline
* Majority CNS Drugs in Preclinical Phase: 396 Drugs
* Majority CNS Drugs for Neurodegenerative Disorders: 228 Drugs in Pipeline
* CNS Disorder Market Drugs: 109 Drugs
* Majority CNS Drugs Marketed for Epilepsy: 24 Drugs
For Report Sample Contact: rajesh@pnspharma.com or :Visit :
https://www.pnspharma.com
Recent Publication
* Global Peptide Therapeutics Market & Clinical Trials Insight
* Global Orphan Drug Clinical Pipeline Insight 2022
PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.
Rajesh Arora
rajesh@pnspharma.com
PNS Pharma
8-9, Ansal Building
Dr. Mukherjee Nagar
Delhi, India
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release US CNS Disorders Drug Pipeline Insight 2014 here
News-ID: 603103 • Views: 368
More Releases from PNS Pharma
Global Gene Therapy Market Opportunity By Clinical Trials Pipeline sales Kymriah …
"Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026" Report Highlight:
o Global Gene Therapy Market Opportunity: > US$ 8 Billion
o Global Gene Therapy Clinical Pipeline: > 1000 Therapies In Clinical Trials
o Commercially Available Gene Therapies: 11
o USA Dominates Global Gene Therapy Pipeline: > 500 Therapies In Clinical Trials
o Cancer Accounts For 50% of Global Gene Therapy Trials
Download Report: https://www.pnspharma.com/buy-report.php?reporttitle=Global-Gene-Therapy-Market-Opportunity-%26-Clinical-Trials-Insight-2026
Over the years, gene therapy has been highly responsible for decreasing the mortality rate…
Global Orphan Drug Market Clinical Trials Pipeline Report Market Study 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights:
o Global Orphan Drug Market Opportunity: US$ 300 Billion
o US Dominates Global Orphan Drug Market: 50% Market Share
o US Orphan Drug Opportunity To Surpass: US$ 150 Billion
o Global Orphan Drug Clinical Insight: More Than 900 Drugs
o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs
o Oncology To Dominate Orphan Drug Development: 35% Share
o FDA & EMA Regulations For Orphan Drugs
o Orphan Drug Designation Criteria…
Global Rare Disease Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights:
o Global Orphan Drug Market Opportunity: US$ 300 Billion
o US Dominates Global Orphan Drug Market: 50% Market Share
o US Orphan Drug Opportunity To Surpass: US$ 150 Billion
o Global Orphan Drug Clinical Insight: More Than 900 Drugs
o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs
o Oncology To Dominate Orphan Drug Development: 35% Share
o FDA & EMA Regulations For Orphan Drugs
o Orphan Drug Designation Criteria…
Global Orphan Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights:
o Global Orphan Drug Market Opportunity: US$ 300 Billion
o US Dominates Global Orphan Drug Market: 50% Market Share
o US Orphan Drug Opportunity To Surpass: US$ 150 Billion
o Global Orphan Drug Clinical Insight: More Than 900 Drugs
o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs
o Oncology To Dominate Orphan Drug Development: 35% Share
o FDA & EMA Regulations For Orphan Drugs
o Orphan Drug Designation Criteria…
More Releases for CNS
Central Nervous System (CNS) Therapeutic Market Central Nervous System (CNS) The …
MARKET INTRODUCTION
The central nervous system (CNS) is the control panel of the body, which is responsible for cognition, movement, senses and emotions. Central nervous system diseases, is a group of neurological disorders that affect the structure or function of the brain or spinal cord, which collectively form the central nervous system (CNS). The CNS diseases include neurodegenerative diseases, neurodevelopmental diseases and traumatic injuries. Drugs such as analgesics, anesthetics, nervous system…
Neuro Critical Care Market Insights in terms of volume and value 2018 to 2028(Mo …
Neuro critical care is an emerging field that combines the specialties that link neurology, neurosurgery, and critical care. Just as the field has evolved from primary focus on post-operative care to elective neurosurgical patients, the focus towards the resuscitation of neurological emergency cases such as traumatic brain injury or subarachnoid hemorrhage, which remain a clinical challenge. The neuro critical care market is strongly driven by the increasing focus, awareness, and…
CNS Therapeutics Technology Forecast Research Report 2018-2025
The Global CNS Therapeutics Market 2018-2028 report offers a detailed analysis of the industry, with market size forecasts covering the next ten years. This report will also analyze factors that influence demand for tactical communication, key market trends, and challenges faced by industry participants.
The CNS Therapeutics industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. With the…
Central Nervous System (CNS) Biomarkers Market - World is Witnessing a Rapid Gro …
Biomarkers are used to indicate the biological state of a process, pathogenic process or therapeutic action. Biomarkers facilitate understanding the development of a chronic disease, relationship between exposure to environmental chemicals and identification of subgroups of people who are relatively at high risk of developing disease.
Download Exclusive Sample of this Report: http://bit.ly/2fOOwAv
Continued development in related technologies such as genomics, proteomics and imaging system has accelerated the development of biomarkers.…
CNS Therapeutics Market Research Report 2016
“Global CNS Therapeutics Market Research Report 2016” Order This Report by calling BigMarketResearch.com at +1-971-202-1575
Notes:
Production, means the output of CNS Therapeutics
Revenue, means the sales value of CNS Therapeutics
This report studies CNS Therapeutics in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering
Pfizer, Inc. (USA)
Johnson & Johnson (USA)
Bristol-Myers Squibb…
CNS Disorders and Therapeutics 2016
We are pleased to invite you to the “2nd International Conference and Exhibition on Central Nervous System Disorders and Therapeutics” scheduled from December 05-07, 2016 in Dubai, UAE.
For three days, you will experience about the effect of greater innovation in the field of CNS and Neurology with the theme, “Accelerate the Diagnosis, Prevention & Management of CNS disorders”.
We would like to formally invite you to come and share…